Change in the Company Name of Western Pharmaceutical Subsidiaries of Kyowa Hakko Kirin
January 29, 2016
Tokyo, Japan, January 29th, 2016 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo 4151; President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announces that it will change the name of all its western pharmaceutical subsidiaries, using "Kyowa Kirin" as a common company brand name. Every subsidiary will begin officially operating under this new company trade name at various points during 2016.
Kyowa Hakko Kirin is expanding its business globally and, as shown in its business vision, "Kyowa Hakko Kirin will be a Japan-based Global Specialty Pharmaceutical Company contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the art antibody technologies mainly in the core therapeutic areas of oncology, nephrology and immunology". The company plans to launch late stage development products in the US and Europe in this mid-term business plan. Kyowa Hakko Kirin's decision to unify all of its western pharmaceutical subsidiaries under one name, "Kyowa Kirin", is in pursuit of its aim to become a Global Specialty Pharmaceutical Company.
"I am convinced that a unified brand name will strengthen interaction and integration in our group." said Nobuo Hanai, Ph.D., President and CEO of Kyowa Hakko Kirin. "This will assist us in leaping forward as a Global Specialty Pharmaceutical Company, creating innovations across the group's various business bases."
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
